摘要
由于门冬氨酸鸟氨酸能参与尿素代谢而降低血氨，在纠正肝性脑病和亚临床型肝性脑病的临床应用中已得到认可。并随着应用经验的积累，发现门冬氨酸乌氨酸在促进肝细胞修复，减轻肝细胞损害等方面有一定作用，已在肝脏的围手术期和放、化疗中作为护肝辅助治疗。而且有很好的安全性。
It is confirmed that L-ornithine-L-aspartate has clinical efficacy in treating hepatic encephalopathy and subclinical encephalopathy because it is shown to reduce ammonia by improving ammonia metabolism. With the accumulation of clinical experience, it is also shown that L-ornithine-L-aspartate has efficacy in promoting liver cell repair and preventing the damage of liver. Moreover, it plays a role of assistance treatment in radiotherapy, chemotherapy and liver surgery for protecting liver cell. And it is safe with dosage of L-ornithine-L-aspartate in 10g-20g per day.
出处
《世界感染杂志》
2007年第5期415-418,共4页
World Journal of Infection
关键词
门冬氨酸鸟氨酸
乙型肝炎
肝性脑病
L-ornithine-L-aspartate
hepatitis B
hepatic encephalopathy
